Shares of Horizon Pharma PLC (NASDAQ:HZNP) have been assigned a consensus rating of “Buy” from the fifteen brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $17.82.

Several equities research analysts recently weighed in on HZNP shares. Piper Jaffray Companies set a $17.00 price objective on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Tuesday, July 25th. Mizuho reaffirmed a “hold” rating and issued a $12.00 price objective (up previously from $9.00) on shares of Horizon Pharma PLC in a report on Monday, August 28th. Zacks Investment Research downgraded shares of Horizon Pharma PLC from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Horizon Pharma PLC in a report on Friday, July 14th. Finally, ValuEngine downgraded shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st.

TRADEMARK VIOLATION NOTICE: “Horizon Pharma PLC (HZNP) Receives Consensus Recommendation of “Buy” from Brokerages” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/11/05/horizon-pharma-plc-hznp-receives-consensus-recommendation-of-buy-from-brokerages.html.

Shares of Horizon Pharma PLC (NASDAQ HZNP) traded up $0.33 during trading hours on Friday, hitting $14.17. 3,438,778 shares of the company were exchanged, compared to its average volume of 1,935,691. The company has a current ratio of 1.61, a quick ratio of 1.46 and a debt-to-equity ratio of 1.83. The company has a market capitalization of $2,314.73, a price-to-earnings ratio of 8.43, a PEG ratio of 2.16 and a beta of 1.32. Horizon Pharma PLC has a fifty-two week low of $9.45 and a fifty-two week high of $21.98.

Horizon Pharma PLC (NASDAQ:HZNP) last released its earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.29. The firm had revenue of $289.51 million during the quarter, compared to analyst estimates of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The firm’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.56 earnings per share. analysts forecast that Horizon Pharma PLC will post 0.73 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of Montreal Can increased its holdings in shares of Horizon Pharma PLC by 16.3% in the 2nd quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 1,378 shares during the period. Sheaff Brock Investment Advisors LLC increased its holdings in shares of Horizon Pharma PLC by 5.0% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 500 shares during the period. Family Management Corp acquired a new position in shares of Horizon Pharma PLC in the 2nd quarter valued at about $131,000. Ballentine Partners LLC acquired a new position in shares of Horizon Pharma PLC in the 2nd quarter valued at about $139,000. Finally, Teacher Retirement System of Texas increased its holdings in shares of Horizon Pharma PLC by 12.8% in the 2nd quarter. Teacher Retirement System of Texas now owns 12,941 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 1,466 shares during the period. Hedge funds and other institutional investors own 82.55% of the company’s stock.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.